<< Read Full Article
<< Read Full Article
Celgene Gets Global Oomph From Pharmion Deal
- Loading Comments...
Biotech firm Celgene(CELG Quote) is buying Pharmion(PHRM Quote) in a $2.9 billion cash-and-stock transaction that merges two fast-growing marketers of blood cancer drugs and gives an immediate boost to Celgene's nascent European commercial operations.
Celgene has agreed to pay $72 a share for Pharmion, a 46% premium over the company's closing price Friday. Pharmion shareholders will receive $25 in cash and $47 in Celgene stock, with the exact number of shares to be determined later.
Celgene says the purchase of Pharmion will be dilutive to earnings in 2008, accretive in 2009. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,471.50 | 1,106.41 | 2,190.31 | 35.40 |
Oil *
71.66
|
|
UP
65.67
|
UP
4.06
|
DOWN
0.55
|
UP
0.58
|
10 Yr
3.54%
SPDR Gold
109.32
|
|
+0.63%
|
+0.37%
|
-0.03%
|
+1.67%
|
Data delayed 20 minutes |


Connect with TheStreet